

## U.S. Value Equity Strategy Notes Fourth Quarter 2024 (1 October – 31 December 2024)

The Brandes U.S. Value Equity Strategy declined 0.09% (gross of fees) in the quarter, outperforming its benchmark, the Russell 1000 Value Index, which fell 1.98%.

### **Positive Contributors**

Despite the benchmark's overall decline, the financials sector appreciated in the quarter, and our overweight and stock selection aided relative performance. Our positions in large money center banks, notably Wells Fargo and Citigroup, benefited from robust earnings results and market anticipation of a slowdown in rate cuts by the Federal Reserve. Additionally, financial technology firm Fiserv lifted returns.

Holdings in industrials also contributed positively to performance, led by aerospace company CAE and machinery firm Gates Industrial.

Other contributors included technology-related holdings Flex and Alphabet, as well as pharmaceutical distributor McKesson. All three companies reported earnings that exceeded consensus estimates, with Alphabet receiving an additional boost from the unveiling of its new quantum computing chip.

### **Performance Detractors**

Health care was one of the worst-performing sectors in the benchmark. Consequently, our overweight hurt relative returns, although our holdings overall held up better than those in the index.

HCA Healthcare, Cigna, Sanofi, and CVS all declined amid market concerns for potential regulatory changes, including one that involves how health insurers recognise profits in their pharmacy benefit manager (PMB) businesses. While we're monitoring the evolving environment, we'd like to note that both Cigna and CVS have already taken actions over the past couple of years to improve transparency and move increasingly toward a more simplified fee-for-service model. In our experience, the market tends to overreact to the uncertainty related to potential health care reform, which often becomes a focal point around elections. This can create appealing investment opportunities. With both Cigna and CVS trading at less than 10x forward earnings, we feel the market concerns have been more than priced in the shares.

Outside health care, detractors included our semiconductor holdings Micron and Qorvo.

Despite its positive earnings results, Qorvo declined after revising its earnings guidance lower, primarily because its smartphone end-market remains cyclically depressed as demand has normalized from its elevated levels during the pandemic. The company also cited a shift in consumer preference—especially in the Chinese market—toward lower-end smartphones as a potential demand headwind for its semiconductors, given that Qorvo focuses more on the higher-end smartphone market. At its current valuation based on below mid-cycle earnings, we believe Qorvo continues to offer an attractive margin of safety (the discount of market price to our estimate of intrinsic value). However, due to the increased risks from the market shift, we have maintained the position at a smaller allocation.

Meanwhile, Micron tumbled on the weakness in the semiconductor market. We trimmed our position in Micron earlier in the year when the market was excited about memory semiconductors' role in the artificial intelligence (AI) buildout, but we then purchased more shares toward the end of the quarter after the stock declined on smartphone and PC (personal computer) weakness. Micron should remain quite cyclical in the consolidated memory industry, but we feel it is well positioned to improve its share in high-bandwidth memory needed for AI.

### **Select Activity in the Quarter**

We initiated positions in utility firm Evergy, food service company Sysco, and aerospace material company Hexcel.

Formed through the merger of Westar Energy and Great Plains Energy in 2018, Evergy serves approximately 1.7 million customers in Kansas and Missouri. Evergy generates the majority of its power from its own renewable and nuclear generating capacity, with the remainder coming from coal, natural gas, and renewable power purchase

agreements. Evergy has historically traded at a discount relative to other utilities in the U.S. due to its lower growth outlook and challenging regulatory environment. However, we believe there is good potential for improvement.

Firstly, the growing need for power from data centers in Evergy's service region should help accelerate growth, along with the transition to electric vehicles. Evergy is in advanced stages of negotiations with several potential customers, including data centers and electric vehicle battery plants. Although Evergy's share price rose in 2024, we think the market still underestimates the company's long-term growth potential since many of its projects will not be reflected in its financials for several years.

Secondly, recent regulatory enhancements in Kansas and Missouri have improved capital investment recovery visibility. Going forward, Evergy should have more consistent earnings with strengthened cash flows, which will allow for faster capital deployment, reduced equity needs, and improved credit metrics. As a regulated utility, Evergy will be able to continue to invest in the energy transition (shifting its power generation from coal to renewables) and in the modernisation of its transmission and distribution infrastructure, enabling it to earn a regulated and robust return on those investments.

Overall, we see Evergy as a compelling value opportunity due to its attractive valuation and financial metrics, coupled with its opportunity to grow through grid modernisation and a potentially more supportive regulatory environment.

Founded in 1946, Hexcel (HXL) is a manufacturer of carbon fiber composite materials and composite engineered structures for commercial aerospace, defense, space, and industrial end-markets. HXL's composites are key inputs for a variety of applications, including aerostructures (wings, fuselage, engine casings), primary structures on spacecraft, and carbon ceramic brakes for high-performance cars. About 90% of its revenues comes from aerospace programs (commercial and defense), with HXL active on all modern Airbus and Boeing platforms, as well as over 100 defense programs.

Since the pandemic, HXL has faced industry-wide skilled-labor shortages, supply-chain bottlenecks, and input cost inflation. These challenges have slowed the production ramps on key commercial platforms and compressed HXL's margins as the company operates under fixed-price contracts. Additionally, HXL had increased capacity ahead of these production ramps and thus has been operating at suboptimal efficiency on a substantial fixed-cost base. While these headwinds have started to ease and HXL's fundamentals have moved closer to pre-pandemic levels, lingering supply-chain issues slowed production on commercial aerospace platforms at Airbus and Boeing, prompting questions about the pace of normalisation. The outlook has been further dampened by regulatory hurdles and the Boeing labor strike, though it should be noted that HXL's commercial exposure is primarily to Airbus.

Despite the supply-chain issues starting to alleviate, the market seems to extrapolate HXL's prospects from its short-term challenges, resulting in the decline of its share price. However, we expect the environment to gradually normalise and HXL to resume its recovery to pre-pandemic levels. Among aerospace composite manufacturers, HXL holds a leading market share and is the most vertically integrated player, with strong capabilities throughout the value chain. There is also potential for secular growth from new aircraft designs that will incorporate more carbon fiber content as the industry seeks to reduce emissions. This should bode well for demand for HXL's products in the long term. Furthermore, we appreciate HXL's attractive financial characteristics, including a solid balance sheet, healthy free-cash-flow generation, and an operating culture focused on return on invested capital metrics. We purchased shares during the quarter as we felt the company's financial characteristics and leadership position were clouded by current headwinds impacting the stock price.

### **Year-to-Date Briefing**

The Brandes U.S. Value Equity Strategy rose 16.16% in 2024, outperforming its benchmark, the Russell 1000 Value Index, which increased 14.37%.

Value stocks underperformed the overall market (Russell 1000 Value vs. Russell 1000) as the solid performance of large technology companies boosted the broader index. In fact, just three companies (Nvidia, Broadcom, and Meta) drove the majority of the outperformance of the Russell 1000 Index relative to the Russell 1000 Value Index for the year.

For the portfolio, outperformance was primarily driven by stock selection across most sectors. Financials was the best-performing sector in the value benchmark, up over 30%. Our overweight and stock selection in the sector benefited relative performance. Leading contributors included Fiserv, Wells Fargo, Bank of New York Mellon, and Citigroup. Other contributors included technology-related holdings such as Flex and Alphabet, as well as recent purchases such as CAE and Entergy.

Health care was one of the worst-performing sectors, roughly flat on the year, and our overweight hurt relative performance. At the holding level, notable detractors included Fortrea, CVS, and Merck. Additionally, energy firm Halliburton weighed on returns, as did semiconductor company Qorvo.

### **Current Positioning**

The Brandes U.S. Value Equity Strategy continues to hold meaningful allocations to the economically sensitive financials sector and the more defensive health care sector, while maintaining underweights in real estate. We also remain underweight in consumer staples and utilities, although the gaps have narrowed as we have identified more value opportunities in these sectors over the past few quarters. Additionally, we have found more opportunities in industrials and are now slightly overweight to the sector, versus modestly underweight at the start of the year. In contrast, we have pared some of our holdings in the health care, financials, and technology sectors, even though they remain areas of overweight for the portfolio.

Following the outperformance of growth stocks these past two years, value stocks are now trading near the largest discount relative to growth stocks since the inception of the style indices (Russell 1000 Growth vs. Russell 1000 Value). This valuation disparity is evident across various metrics, such as price/earnings, price/cash flow, and enterprise value/sales. Historically, such valuation differentials have often signaled attractive future returns for value stocks over longer-term horizons. This is encouraging for us, as our strategy, guided by our value philosophy and process, has had the tendency to outperform the benchmark when value stocks outperformed the Russell 1000 Index.

With only a relatively small number of companies—mostly tech-related—driving the broader market’s performance, equity concentration levels have increased materially in popular indices. For example, the eight largest companies contributed the majority of the returns in the Russell 1000 Index this year and now account for over 30% of the index. In our view, this highlights the potential diversification benefits of having a value strategy to complement many investors’ increasingly concentrated and technology-centered exposure, as the largest companies in the broader index also represent the largest weights in various factor indices—with the value index being an exception.

Looking ahead, we remain confident that the current fundamentals of our holdings bode well for the long term, and we are excited about the strategy’s prospects.

Term definitions: <https://www.brandes.com/termdefinitions>

The Russell 1000 Index with gross dividends measures performance of the large cap segment of the U.S. equity universe.

The Russell 1000 Value Index with gross dividends measures performance of the large cap value segment of the U.S. equity universe. Securities are categorised as growth or value based on their relative book-to-price ratios, historical sales growth, and expected earnings growth.

The Russell 1000 Growth Index with gross dividends measures performance of the large cap growth segment of the U.S. equity universe. Securities are categorised as growth or value based on their relative book-to-price ratios, historical sales growth, and expected earnings growth.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account’s portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach

tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

**Ireland/Europe:** FOR PROFESSIONAL INVESTOR USE ONLY. Issued by Brandes Investment Partners (Europe) Limited (Brandes Europe), Alexandra House, The Sweepstakes, Ballsbridge, Dublin, D04 C7H2, Ireland. Registered in Ireland Number 510203. Authorised and regulated by the Central Bank of Ireland. This report is being provided for information purposes only, no representation or warranty is made, whether express or implied as to the accuracy or completeness of the information provided. To the fullest extent permitted by law Brandes Europe shall not be liable for any loss or damage suffered by any person as a result of the receipt of this report. Recipients of this report should obtain their own professional advice. The distribution of this report may be restricted by law. No action has been or will be taken by Brandes Europe to permit the possession or distribution of this report in any jurisdiction where action for that purpose may be required. Accordingly, this report may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this report is communicated should inform themselves about and observe any such restrictions. This information is being issued only to, and/or is directed only at (i) persons who have professional experience in matters relating to investments or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This report is a confidential communication to, and solely for the use of, the persons to whom it is distributed to by Brandes Europe.